Results 61 to 70 of about 438,950 (335)

Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer

open access: yesActa Médica Portuguesa, 2019
The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors.
Andreia Tereso   +3 more
doaj   +1 more source

Nonreceptor Tyrosine Kinases in Prostate

open access: yesNeoplasia, 2007
Carcinoma of the prostate (CaP) is the most commonly diagnosed cancer in men in the United States. Signal transduction molecules such as tyrosine kinases play important roles in CaP. Src, a nonreceptor tyrosine kinase (NRTK) and the first proto-oncogene discovered is shown to participate in processes such as cell proliferation and migration in CaP ...
Yu-Ming Chang   +2 more
openaire   +4 more sources

Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
We used whole exome and RNA‐sequencing to profile divergent genomic and transcriptomic landscapes of microsatellite stable (MSS) and microsatellite instable (MSI) colorectal cancer. Alterations were classified using a computational score for integrative cancer variant annotation and prioritization.
Efstathios‐Iason Vlachavas   +15 more
wiley   +1 more source

Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review

open access: yesFrontiers in Pharmacology
In light of the expected increase in the prevalence of diabetes mellitus due to an aging population, sedentary lifestyles, an increase in obesity, and unhealthy diets, there is a need to identify potential pharmacological agents that can heighten the ...
Takudzwa Mugiya   +4 more
doaj   +1 more source

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

open access: yesHaematologica, 2013
Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Aziz Nazha   +12 more
doaj   +1 more source

Metastatic melanoma-A review of current and future perspective [PDF]

open access: yesarXiv, 2020
Metastatic Melanoma, the fifth most common cancer in the western countries and the most common malignancy diagnosed in United States present itself as the most lethal treatment resistant cancer worldwide. In addition to the reactive oxygen species(ROS), mutations in the genes encoding receptors and non-receptor tyrosine/serene/threonine protein kinases
arxiv  

Benchmarking the performance of DFT functionals for absorption and fluorescence spectra of EGFR inhibitor AG-1478 using TD-DFT [PDF]

open access: yesarXiv, 2021
Optical spectra (UV-vis and fluorescence) are sensitive to the chemical environment and conformation of fluorophores and therefore, are ideal probes for their conformation and solvent responses. Tyrosine kinase inhibitors (TKI) such as AG-1478 of epidermal growth factor receptor (EGFR) when containing a quinazolinamine scaffold are fluorophores ...
arxiv  

CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma

open access: yesMolecular Oncology, EarlyView.
CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan   +6 more
wiley   +1 more source

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

open access: yesRevista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta   +8 more
doaj   +1 more source

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

open access: yesMolecular Cancer, 2018
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting from the t(9;22)(q34;q11) chromosomal translocation, is thought to be the driver event responsible for initiation and maintenance of chronic myeloid ...
Simona Soverini   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy